Approach to immune checkpoint inhibitor (ICI) nephrotoxicity and rechallenge
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/32775813/

Practical suggestions for the diagnosis and management of hypertension before, during, and after the start of anticancer therapy
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/36621810/

Cancer Therapy Related Hypertension
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/36621810/

Hypomagnesemia
📌 Manifestations and its association with cancer
📌 Causes in patients with cancer
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky

👉 pubmed.ncbi.nlm.nih.gov/37086496/

Individualized management of malignancy-associated hypercalcemia
#ISNWCN 🇯🇵 #WCN26 🇯🇵 #WCN2026 🇯🇵
#Onconephrology 🦀 #Nephpearls #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/41623290/

ICYMI

recording up now youtu.be/4EiLrH2hUCA?...

@sbrimble.bsky.social #onconephrology #NephGR #NephSky

The subdistribution hazard ratios for progressive kidney dysfunction are shown for each drug group compared with their respective propensity score–matched cohort. The blue dots represent the hazard ratio and 95% CIs. Due to wide confidence intervals, MET inhibitors results reported in the text and not displayed here. MET inhibitors are included in overall treated group. Model is adjusted for hypertension, diabetes, ischemic heart disease, congestive heart failure, chronic obstructive pulmonary disease, cirrhosis, age, sex, race, body mass index, and eGFR before drug start. ALK indicates anaplastic lymphoma kinase; BRAF, B-Raf proto-oncogene, serine/threonine kinase; CDK4/6, cyclin dependent kinase 4 or 6; EGFR, endothelial growth factor receptor; ERBB2, human epidermal growth factor receptor 2; PARP, poly(adenosine diphosphate-ribose) polymerase; VEGFR, vascular endothelial growth factor receptor.

large cohort study of
CDK 4/6
BRAF
EGFR
VEGF
and other cancer treatments

#OncoNephrology #NephSky #KidneyWk

jamanetwork.com/journals/jam... from Shuchi Anand et al from @stanfordmedicine.bsky.social

ICYMI

Full rounds with some great discussion here

youtu.be/PhHCf97_Gc8?...

#NephGR from @kdjhaveri.bsky.social

#onconephrology

Another treatment-related cause of AKI to remember: Teclistamab, a bispecific monoclonal antibody targeting CD3 and B cell maturation antigen, used for relapsing/refractory MM
More info: academic.oup.com/ndt/article/...
#onconephrology
@ndt-era.bsky.social, @hjanders.bsky.social

Light Chain MGUS Calculator
#Onconephrology 🦀 #Nephpearls #NephSky

H/T @sabinekaram.bsky.social

📱 istopmm.com/lcmgus/
👉 pubmed.ncbi.nlm.nih.gov/36100605/

Synapse: Your Connection to our MSK Authors
Meet: Sheron Latcha

Research Focus: Medicine; Attending

Onconephrology

#Onconephrology #CancerAndKidneys #NephroOncology #KidneyHealthInCancer #RenalComplications

synapse.mskcc.org/synapse/work...

Grand Rounds #Onconephrology Special Session: part 2: " #Kidney #Transplant Considerations with Plasma #Cell Disorders," with Dr. Chris Blosser @uwmedicine.bsky.social #nephsky
Watch: youtu.be/MpHzh6aoh98

Grand Rounds #Onconephrology Special Session: part 1: "Proliferative #Glomerulonephritis with Monoclonal #Immunoglobulin Deposits: Off the Path," with Dr. Bilal Malik @uwmedicine.bsky.social #nephsky #kidney
Watch: youtu.be/7eF2iJv3vqA

Inspired by the onco-nephrology session at the #ERA25 I really enjoyed this paper on tips for common clinical challanges in an onco-nephrology clinic. #onconephrology
url:academic.oup.com/ckj/article/doi/10.1093/...

A population pharmacokinetic approach to compare 51Cr-EDTA and 99 mTc-DTPA clearances in measuring renal glomerular filtration rate in oncopediatrics - Pediatric Nephrology Background 51Cr-EDTA and 99 mTc-DTPA clearances are two reference methods of determining the glomerular filtration rate. The study aimed to compare these two radioisotopic clearance measurements…

A population pharmacokinetic approach to compare 51Cr-EDTA and 99 mTc-DTPA clearances in measuring renal glomerular filtration rate in oncopediatrics
#onconephrology
#openaccess

The SAARC #Onconephrology Course is supported by CKA's Chennai Kidney Associates @ChennaiKidney tie up with @northwellhealth.bsky.social -We are happy that both @drshyambansal @kdjhaveri.bsky.social are course directors. @theisn.org @isn-india.bsky.social
Congrats to all our fellows.

Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury (CP-AKI) from @kdjhaveri.bsky.social
#Nephpearls #Onconephrology 🦀 #NephSky

👉🏼 pubmed.ncbi.nlm.nih.gov/40272825/

💉Immune checkpoint inhibitors: 🦸‍♂️heroes in cancer🦀, 🦹‍♂️villains for kidneys 🫘?

#ICI-AKI can hit both

Glomeruli (C3GN, MCD, vasculitis)
&
Tubulointerstitium (ATIN, ATN, tubulitis)

📖 doi.org/10.34067/KID... 🆕
@asnpublications.bsky.social K360

#Onconephrology #Nephrology #AKI #NephSky #NephPearls

🧰New tools for early ICI-AKI detection!

💧Urine, 🩸 serum, and 📸 imaging markers are changing the game.

Protect kidneys 🫘 , save lives!🌱

🔗 doi.org/10.34067/KID...
@asnpublications.bsky.social K360
@sabinekaram.bsky.social et al

#Nephrology #OncoNephrology #AKI #NephSky #MedSky
#NephPearls

Recovery from acute kidney injury treated with dialysis in patients with multiple myeloma treated with proteasome inhibitors To the Editor,

Happy to share our recent publication on “Recovery from acute kidney injury treated with dialysis in patients with multiple myeloma treated with proteasome inhibitors” @juancarlosqvelez.bsky.social #NDT #OxfordPublications
#OncoNephrology
academic.oup.com/ndt/advance-...

🦀🦴Treatment of Cancer-Associated Hypercalcemia

➡️Start with IV fluids
➡️Then hit osteoclasts with #Bisphosphonates or #Denosumab

But remember, real control = treating the malignancy

🔗 www.nejm.org/doi/full/10....

#Hypercalcemia #Malignancy #OncoNephrology #Nephrology #IM #Oncology #MedSky #NephSky

Case of TMA following Doxil administration. www.kidneymedicinejournal.org/article/S259... #renalpath #nephksy #pathsky #onconephrology

⚡️New drugs, new electrolyte twists⚡️

ICIs, SGLT2i, ARNI, ns-MRA,GLP-1RA—game changers in nephrology, but are we watching their electrolyte impact closely?

This table breaks it down!

👀 Surprised

📖 doi.org/10.1007/s101...

#Nephrology #OncoNephrology #MedSky #Electrolytes

How common is PRRT with Lu 177 dotatate cause Stage 3 AKI requiring dialysis
If common...is there any antidote for the same to treat for renal recovery
@kdjhaveri.bsky.social
#oncoNephrology
#ask_renal
#ASKRenal

NephMadness Va

Mitch Rosner on immune checkpoint inhibitor and renal toxicity

With a #NephMadness #visualAbstract from @corinateodosiu.bsky.social

ajkdblog.org/2023/03/01/n...

#NephSky #ISNWCN #onconephrology

International Society of Nephrology: ISN/ASON Oconephrology Case Presentations ISN and the American Association of Onconephrology (ASON) are collaborating on a series case presentations to further the mission to promote research, clinical activities, and education related to onconephrology.

Check out these #ISNacademy #isneducation cases in #onconephrology. These are cases for now:
💉Immune Check point inhibitor related kidney injury
🔬 Lysozyme nephropathy

x.com/ISNkidneycare/… academy.theisn.org/products/isnas…

International Society of Nephrology: ISN/ASON Oconephrology Case Presentations ISN and the American Association of Onconephrology (ASON) are collaborating on a series case presentations to further the mission to promote research, clinical activities, and education related to onconephrology.

Check out these #ISNacademy #isneducation cases in #onconephrology. These are cases for now:
💉Immune Check point inhibitor related kidney injury
🔬 Lysozyme nephropathy

x.com/ISNkidneycare/… academy.theisn.org/products/isnas…

It will be exciting to meet the @onconephrology leaders in person, listen to their insights, and ask them questions. I am always grateful to @kdjhaveri for publishing his book on #onconephrology, which I highly recommend to my colleagues. #ISNWCN

Multiple Assessments of Glomerular Filtration Rate (GFR) in a Patient Treated with Selpercatinib.

Selpercatinib and artifactual creatinine increase

The authors argue exogenous markers (iohexol) better than endogenous - though 5.2 (iohexol) and 8.6 (Cystatin C) are pretty close?

Correspondence in the @nejm.org

www.nejm.org/doi/full/10.... ($ 🔒)

#NephSky #OncoNephrology

Lenvatinib (VEGFR1-3 FGFR, PDGFR, RET protooncogene KI) induced nephrotic syndrome

from what I can see about 6 weeks to months to resolve after stopping

would people rechallenge with it? Lower dose or best to avoid?

#Askrenal #OncoNephrology
cc @kdjhaveri.bsky.social @aisha-shaikh.bsky.social